Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 46.6% from a year ago
Other current liabilities stood at $3.08M at the end of Q1 FY2026, up 46.6% from a year earlier and down 56.8% from the prior quarter.
Context
- Other current liabilities amounted to 0.6% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +46.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.12M USD
- Year-over-year change
- +92.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.12M | +92.0% |
| FY2024 | 2024-12-31 | 3.71M | +53.7% |
| FY2023 | 2023-12-31 | 2.41M | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Current Liabilities vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 other current liabilities of $3.08M is the 6th highest of the 10 companies compared; the peer median is $7.61M.
- Its year-over-year change of +46.6% is the 3rd highest of 8, against a peer median of +8.3%.
- Other current liabilities amounts to 0.6% of total assets for RAPP, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $332.22M | +16.5% | +11.1% | 18.5% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $24.77M | +294.3% | +42.0% | 16.1% |
| Jun 2026 | $11.2M | -63.1% | +127.9% | 1.5% | |
| Mar 2026 | $11.15M | +65.0% | +89.8% | 2.7% | |
| Mar 2026 | $7.61M | — | +35.8% | 2.8% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $3.08M | +46.6% | — | 0.6% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $1.97M | — | +136.0% | 0.5% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $1.29M | +8.3% | +6.7% | 0.5% |
| Mar 2026 | $498K | -17.0% | +21.7% | 1.4% | |
| Sep 2026 | $0 | -100.0% | +88.3% | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $7.61M | +8.3% | +42.0% | 1.5% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.